Mizuno-Onishi Yuka, Igarashi Tae, Uramoto Kengo, Kaneko Yuichiro, Nagaoka Natsuko, Yoshida Takeshi, Ohno-Matsui Kyoko
Department of Ophthalmology and Visual Science, Institute of Science Tokyo, Tokyo, Japan .
Retina. 2025 Mar 1;45(3):464-471. doi: 10.1097/IAE.0000000000004341.
The natural course of the visual acuity in eyes with myopic macular neovascularization is poor. Intravitreal injections of anti-vascular endothelial growth factor agents have demonstrated safety and efficacy in the short term for managing myopic macular neovascularization. The purpose of this study was to determine the 4-year outcomes of intravitreal aflibercept injections.
A retrospective monocentric study including 49 eyes of 48 patients diagnosed with myopic macular neovascularization. These patients underwent treatment with intravitreal aflibercept using the pro re nata regimen after the first injection. The minimum follow-up duration was 4 years.
The patients had an average age of 63.8 years and an average axial length of 29.7 mm. The mean number of intravitreal aflibercept injections was 1.6, and 30 eyes (61.2%) had a single injection. At the baseline and at 1, 2, 3, and 4 years, the mean best-corrected visual acuities were 20/45, 20/41, 20/43, 20/51, and 20/53, respectively. The differences in the best-corrected visual acuity at the different times from that at the baseline were not significant.
Intravitreal aflibercept therapy with the pro re nata regimen provides a 4-year visual benefit in eyes with myopic macular neovascularization, and it is better than the reported natural course in maintaining the best-corrected visual acuity.
近视性黄斑新生血管形成的眼睛视力自然转归较差。玻璃体内注射抗血管内皮生长因子药物在短期内已证明对治疗近视性黄斑新生血管形成具有安全性和有效性。本研究的目的是确定玻璃体内注射阿柏西普的4年疗效。
一项回顾性单中心研究，纳入48例诊断为近视性黄斑新生血管形成的患者的49只眼睛。这些患者在首次注射后采用按需给药方案接受玻璃体内阿柏西普治疗。最短随访时间为4年。
患者平均年龄63.8岁，平均眼轴长度29.7mm。玻璃体内阿柏西普的平均注射次数为1.6次，30只眼睛（61.2%）仅注射了1次。在基线以及1年、2年、3年和4年时，平均最佳矫正视力分别为20/45、20/41、20/43、20/51和20/53。不同时间点的最佳矫正视力与基线时相比差异无统计学意义。
按需给药方案的玻璃体内阿柏西普治疗可为近视性黄斑新生血管形成的眼睛提供4年的视力改善，在维持最佳矫正视力方面优于所报道的自然转归。
